Skip to main content
OpenTrials
Completed

NCT Number: NCT04754295

Goal-directed Therapy in Neurosurgery.

The purpose of the study is to assess feasibility of future large randomised controled study aimed on assessment of effect of goal-directed therapy on incidence of complications in neurosurgery compared to standard care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Brno

Brno, 625 00, Czechia

About this study

Patients undergoing neurosurgical operations are at risk of inadequate intravascular volume for several reasons. The appropriate fluid management in neurosurgery is a challenge. Goal-directed therapy has been shown to improve the outcome of patients undergoing major surgery. Current knowledge regarding effect of fluid management on patient-orientated outcomes in neurosurgery is limited.

This study is designed as a pilot study with two parallel groups. Patients scheduled to planned brain surgery at the University Hospital Brno will be screened whether they meet the inclusion criteria. After obtaining informed consent, the patient will be randomized to one of the study arms.

In one arm (STANDARD) standard monitoring of vital signs will be introduced. During the operation, perioperative fluid therapy and administration of vasoactive agents will depend entirely at the discretion of the attending anaesthetist. Postoperative therapy will be fully controlled and will depend on the decision of the attending physician. In the second arm (GDT), a non-invasive hemodynamic monitor STARLINK™SV will be introduced in addition to standard monitoring. In this arm, basal infusion with crystalloid balanced solution will be initiated. Additional boluses of fluids will be administered based on haemodynamic monitoring. The primary outcome of the study is a proportion of patients with serious adverse event (SAE). Incidence of SAEs will be compared between study groups. SAE will be defined as unsatisfactory brain tissue relaxation at the end of operation and any intervention for brain oedema postoperatively.

The secondary outcome is to compare proportion of patients with postoperative complications in both groups and length of ICU and hospital stay.

This study will enroll 34 patients in total, 17 in each group. After completion of enrolment of patients the statistical analysis will be performed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age at least 18 years
  • anticipated duration of surgery at least 2 hours
  • signed written consent form
  • American Society of Anesthesiologists (ASA) classification < 4.

Exclusion criteria

  • unavailability of hemodynamic monitor
  • emergency operation
  • ASA ≥4
  • sitting operating position and awake craniotomy
  • awake craniotomy
  • serious cardiorespiratory disorder
  • cardiac arrythmia
  • obesity with BMI above 35 kg/m2

Treatment and study plan

Goal-Directed Therapy

Other

Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring

standard

Other

Administration of fluids and vasoactive drugs guided by standard vital signs monitoring

Primary outcomes

  1. Serious Adverse Events 1

    Time frame: During the Surgery

    Assessment of number of patients with serious adverse event (SAE). SAE is defined as unsatisfactory brain tissue relaxation at the end of surgery assessed by neurosurgeon. Level 3 or 4 of brain tissue relaxation will be considered as unsatisfactory (level 1 - completely relaxed, level 2 - satisfactorily relaxed, level 3 - firm, level 4 - bulging).

  2. Serious Adverse Events 2

    Time frame: 24 hours postoperatively

    Assessment of number of patients with serious adverse event (SAE). SAE is defined as any intervention indicated for treatment of brain edema 24 hours after surgery.

  3. Recruitment rate

    Time frame: through study completion, an average of 6 months

    Proportion of eligible patients who consent to participate in the study.

  4. Completeness of Case Report Forms

    Time frame: through study completion, an average of 6 months

    Proportion of enrolled patients with completed Case Report Form.

Secondary outcomes

  1. Complications

    Time frame: through study completion, an average of 6 months

    Number of patients with pre-defined postoperative complication.

Sponsors and collaborators

Lead sponsor

Brno University Hospital

Other

Registry information

Official study title

Effect of Goal-directed Fluid Management Guided by Non-invasive Device on Incidence of Postoperative Complications in Neurosurgery: Pilot Study

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Feb 15, 2021
Registry last updated
May 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.